The availability of long-acting injectable (LAI) antipsychotics for the treatment of
schizophrenia provides clinicians with options that deliver continuous drug exposure and …

By combining knowledge of pharmacogenetics, therapeutic drug monitoring (TDM) and drug-
drug interactions (DDIs) the author developed a model for personalizing antipsychotic …

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three
long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is …

RBP‐6000 is a novel sustained‐release formulation of buprenorphine for the treatment of
opioid use disorder, which has been designed for once‐monthly (28 days) subcutaneous …

Abstract Background BUP-XR (aka RBP-6000 or SUBLOCADE™) is an extended-release
subcutaneous buprenorphine formulation for the treatment of opioid use disorder. BUP-XR …

The intramuscular (IM) administration of long-acting injectable (LAI) aqueous nano-
/microsuspensions elicits a chronic granulomatous injection site reaction, which recently has …

RBP-7000 is a sustained-release formulation of risperidone for the treatment of
schizophrenia, designed to be administered by once-monthly subcutaneous injection using …

Xia et al.(“Uniform biodegradable microparticle systems for con trolled release” in J.
Controlled Release Jul. 18, 2002;(82 (1): 137-147).* Fleischhacker et al.“Treatment of …

Introduction: Long-acting injectable (LAI) antipsychotics are a useful but underutilized option
in the management of schizophrenia. Areas covered: This is a narrative review of newer LAI …

The last two decades have witnessed profound changes in how advanced computational
tools can help leverage tons of data to improve our knowledge, and ultimately reduce cost …